Divis Lab

The company is collaborating with large pharma clients on ADC chemistry. ADCs are a class of complex molecules used in targeted cancer therapy

Divi’s Lab: Time to take some profit off the table?

With a cash balance of more than Rs 3,200 crore, the company appears well-positioned for further investments to tap upcoming opportunities

Divi’s Lab: Better capex guidance to meet upcoming demand

R&D activities around peptides and contrast media remain the two medium-term growth drivers for the company. US tariffs are a near-term risk.

Divi's Labs shares rise as HSBC raises rating to 'buy', ups target price

The brokerage expects the company's earnings per share to rise at a compounded annual growth rate of 23% between 2024-25 and 2027-28

Divi's Labs shares rise 5% as Citi maintains 'BUY' rating, sees up to 19% upside

The brokerage has given a target of Rs 7,050 per share, an upside potential of 19 percent from its Wednesday's closing at Rs 5,924.5 per share.

Divis Lab: GLP-1 opportunity to unfold in the medium term

Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.

Tata Motors, Asian Paints , Divis Laboratories, LIC & ITI | Stocks On Radar

Tata Motors Q2 consolidated net profit declines 11% to ₹3,343 cr. Asian Paints Q2 Result: Net profit declines 43% on weak demand, revenue dips 5%. Divi's Labs Q2 Results: Net profit rises 46% to Rs 510 crore, revenue at Rs 2,338 crore. Watch here for more details

Divi’s Lab: Custom synthesis business gaining ground

With custom synthesis scope widening and fresh opportunities in off-patented API molecules emerging, Divi’s is on a firm footing

Brokerage Radar: Analysts bullish on Torrent Pharma; CLSA assigns 'outperform' rating to Power Grid, Sun TV

Check the brokerage calls and comments on the stocks in action. Today we cover Torrent Pharma, Divi's Lab, Ashok Leyland among others following their Q4 results.

Live: Nifty gives up gains after coming close to record high | Nestle in focus | Closing Bell

The Sensex was up 33.28 points or 0.05 percent at 73,937.19, and the Nifty was down 1.60 points or 0.01 percent at 22,451.70. About 2554 shares advanced, 871 shares declined, and 72 shares unchanged. For more watch Closing Bell with Nandita Khemka and Yatin Mota.

Weekly Tactical Pick: A pharma stock set to ride emerging opportunities

With the emerging threat of the new COVID variant, JN.1, equity markets are likely to be volatile in the coming days. Defensive stocks like Divi’s Lab will merit attention

Divi’s Lab: FY25 to witness sizeable improvement in performance

The company is enthusiastic about the opportunities in contrast media and peptide building blocks, which shall unfold in 2-5 years

Emerging opportunities can help re-rate Divi’s lab

Divi’s Lab is a leading API manufacture of India, primarily known for its market share in molecules like naproxen, gabapentin, and dexamethrophan. While its performance in last few quarters has been impacted due to multiple headwinds, it is well positioned for the new earnings drivers like contrast media and completion of new facility next year

Weekly Tactical Pick: Divi’s Lab is better placed to ride the API up-cycle

Even though pricing headwinds remain in the generic portfolio, we believe new growth opportunities can reinvent the earnings trajectory for the company.

Divi’s Lab: Emerging opportunities can re-invent the earnings wheel

Though pricing headwinds remain in the generic portfolio, we believe growth opportunities in the field of contrast media, peptide building blocks and carot-enoids can reinvent the earnings trajectory for the company.

Live: Nifty ends positive; Divis Lab among gainers, Britannia among losers | Bajar Gupshup

The equity indices started the week on a positive note and ended higher for the second consecutive session on August 7 with Nifty near 19,600 supported by information technology, healthcare and realty stocks. At close, the Sensex was up 232.23 points or 0.35 percent at 65,953.48, and the Nifty was up 80.30 points or 0.41 percent at 19,597.30. Amid mixed global cues, the market started in the green, while witnessing some profit booking at higher levels in the first half. But extended buying in the second half helped the indices to close near the day's high.

Robust growth in banks, NBFCs; engineering space sees strong order flow: Saurabh Mukherjea

Marcellus Investment Managers has doubled its position in Divis Labs, which now constitutes approximately 7-8 percent of its portfolio.

Divi’s Lab: Sequential improvement, but long way to go

An improvement in gross margins is on the cards over the next three to four quarters

Gainers & Losers: 10 stocks that moved the most on April 12

The Sensex closed 0.39 percent higher at 60,392.77 and the Nifty 0.51 percent at 17,812.40. As many as 1,997 shares advanced, 1,413 declined and 108 shares remained unchanged

Divi’s Labs: Focus on green chemistry

The drug firm is set to benefit from investments in productivity and new product range

Divis Lab Q1 PAT seen up 27.3% YoY to Rs 709 cr: ICICI Direct

Net Sales are expected to increase by 18 percent Y-o-Y (down 8.1 percent Q-o-Q) to Rs 2,314.5 crore, according to ICICI Direct.

Divi’s Labs: Steady margin profile amid cost headwind

Earnings trigger for the medium term is Contrast Media API opportunity, where there is limited competition

Aether IPO | This niche chemical player is a leader of the pack. How?

The company’s success depends on identifying the molecule/product opportunity, investing behind R&D and implementing processes/integration to scale it up

Indian chemical industry in a sweet spot as Europe struggles

The ongoing energy crisis which disproportionately impacts Europe can further help Indian firms reach out to export markets of European chemical companies

Hikal: Green integrity in the spotlight, more than financials

We are entering increasing interest rate scenario. Liquidity is drying which simply means institutional fund flows would be much more selective and sensitive to quality aspect